A Phase 2 Study of SU011248 (Sunitinib Malate) in Von Hippel-Lindau Syndrome.

Trial Profile

A Phase 2 Study of SU011248 (Sunitinib Malate) in Von Hippel-Lindau Syndrome.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Feb 2012

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Haemangioblastoma; Neuroendocrine tumours; Renal cancer
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 29 Jun 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 09 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Jan 2011 Planned end date changed from Dec 2010 to Dec 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top